Complete responses to odronextamab in two patients with diffuse large B-cell lymphoma refractory to chimeric antigen receptor T-cell therapy.
Journal Information
Full Title: Br J Haematol
Abbreviation: Br J Haematol
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"CONFLICT OF INTEREST Srikanth R. Ambati, Jurriaan Brouwer‐Visser, Nathalie Fiaschi, Vladimir Jankovic, Gavin Thurston, Raquel P. Deering and Aafia Chaudhry hold stock or stock options for and are employees of Regeneron Pharmaceuticals, Inc. Jon Arnason reports participation on a data safety monitoring board or advisory board for Bristol Myers Squibb, Juno, and Regeneron Pharmaceuticals, Inc., outside the submitted work."
"This study was supported by Regeneron Pharmaceuticals. Editorial support was provided by Lewis Cawkwell of Arc, a division of Spirit Medical Communications Group Limited, and funded by Regeneron Pharmaceuticals."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025